Anna Rita Bentivoglio

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7019374/anna-rita-bentivoglio-publications-by-year.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162 11,948 48 107 h-index g-index citations papers 166 6.6 13,560 5.42 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
162	Botulinum toxin injection for the treatment of chronic anal fissure: uni- and multivariate analysis of the factors that promote healing <i>International Journal of Colorectal Disease</i> , 2022 , 37, 693	3	O
161	Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
160	Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. <i>Neurological Sciences</i> , 2021 , 42, 5177-5181	3.5	O
159	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 70-74	3.6	1
158	Frameless stereotaxy in subthalamic deep brain stimulation: 3-year clinical outcome. <i>Neurological Sciences</i> , 2021 , 42, 259-266	3.5	1
157	Deep brain stimulation in Fragile X syndrome with tardive dystonia. <i>Neurological Sciences</i> , 2021 , 42, 29)8 <i>7</i> 5. 3 98	8 9 O
156	A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study. <i>GeroScience</i> , 2020 , 42, 1323-1334	8.9	10
155	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2020 , 127, 881-891	4.3	2
154	Mitochondrial Signatures in Circulating Extracellular Vesicles of Older Adults with Parkinson's Disease: Results from the EXosomes in PArkiNson's Disease (EXPAND) Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	41
153	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 40-43	3.6	10
152	GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020 , 35, 2106-2111	7	35
151	Idiopathic Non-task-Specific Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020 , 35, 2038-2045	7	13
150	Prevalence of Huntington's disease in Southern Sardinia, Italy. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 54-57	3.6	6
149	Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson's disease. <i>Npj Parkinsonis Disease</i> , 2020 , 6, 26	9.7	2
148	Prevalence of Obsessive-Compulsive Symptoms in Elderly Parkinson Disease Patients: A Case-Control Study. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 167-175	6.5	4
147	Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study. <i>Movement Disorders</i> , 2019 , 34, 1516-1527	7	32
146	Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson's Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	38

(2016-2019)

145	Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study. <i>Experimental Gerontology</i> , 2019 , 128, 110766	4.5	18
144	The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 42-47	3.6	27
143	Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients: A Case-Control Study. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	6
142	Extradural motor cortex stimulation improves gait, speech, and language in a patient with pure akinesia. <i>Brain Stimulation</i> , 2018 , 11, 1192-1194	5.1	6
141	Association of metabolic syndrome with falls in patients with Parkinson's disease. <i>Clinical Nutrition</i> , 2017 , 36, 559-563	5.9	7
140	Wake and Sleep EEG in Patients With Huntington Disease: An eLORETA Study and Review of the Literature. <i>Clinical EEG and Neuroscience</i> , 2017 , 48, 60-71	2.3	17
139	DYT2 screening in early-onset isolated dystonia. European Journal of Paediatric Neurology, 2017, 21, 269	9-32871	7
138	Use of ACE-inhibitors and falls in patients with Parkinson's disease. <i>Gait and Posture</i> , 2017 , 54, 39-44	2.6	8
137	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology, The</i> , 2017 , 16, 701-711	24.1	161
136	Sleep-related modifications of EEG connectivity in the sensory-motor networks in Huntington Disease: An eLORETA study and review of the literature. <i>Clinical Neurophysiology</i> , 2017 , 128, 1354-1363	3 4.3	6
135	Subjective Assessment of Sleep in Huntington Disease: Reliability of Sleep Questionnaires Compared to Polysomnography. <i>Neurodegenerative Diseases</i> , 2017 , 17, 330-337	2.3	9
134	Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel. <i>Parkinsonism and Related Disorders</i> , 2017 , 42, 109-111	3.6	4
133	Patient's Loss of Empathy Is Associated With Caregiver Burden. <i>Journal of Nervous and Mental Disease</i> , 2016 , 204, 717-22	1.8	14
132	E2 Progression of motor subtypes in huntington disease: a six-year follow-up study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A45.2-A45	5.5	
131	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 421-424	2.2	1
130	Motor-related sleep disorders in Huntington disease. A comment on: Neute et al.: "Nocturnal agitation in Huntington disease is caused by arousal-related abnormal movements rather than by rapid eye movement sleep behavior disorder" by Neutel et lal. <i>Sleep Medicine</i> , 2016 , 20, 172-3	4.6	7
129	Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity. <i>Journal of the Neurological Sciences</i> , 2016 , 362, 344-7	3.2	17
128	Rehabilitation of hypomimia in Parkinson's disease: a feasibility study of two different approaches. <i>Neurological Sciences</i> , 2016 , 37, 431-6	3.5	6

127	Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic Form. <i>PLoS ONE</i> , 2016 , 11, e0163980	3.7	8
126	Mild cerebello-thalamo-cortical impairment in patients with normal dopaminergic scans (SWEDD). <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 23-8	3.6	16
125	Impulsive-compulsive behaviors in parkin-associated Parkinson disease. <i>Neurology</i> , 2016 , 87, 1436-1441	6.5	41
124	Working on asymmetry in Parkinson's disease: randomized, controlled pilot study. <i>Neurological Sciences</i> , 2015 , 36, 1337-43	3.5	17
123	Pedunculopontine nucleus stimulation in Parkinson's disease dementia. <i>Biological Psychiatry</i> , 2015 , 77, e35-40	7.9	11
122	Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview. <i>Toxicon</i> , 2015 , 107, 129-	4:0 8	40
121	Reduced facial expressiveness in Parkinson's disease: A pure motor disorder?. <i>Journal of the Neurological Sciences</i> , 2015 , 358, 125-30	3.2	35
120	Clinical differences between botulinum neurotoxin type A and B. <i>Toxicon</i> , 2015 , 107, 77-84	2.8	49
119	Lithium Treatment in Patients With Huntington's Disease and Suicidal Behavior. <i>Movement Disorders</i> , 2015 , 30, 1438	7	9
118	Polysomnographic Findings and Clinical Correlates in Huntington Disease: A Cross-Sectional Cohort Study. <i>Sleep</i> , 2015 , 38, 1489-95	1.1	42
117	Rapid eye movement sleep behavior disorder: a window on the emotional world of Parkinson disease. <i>Sleep</i> , 2015 , 38, 287-94	1.1	9
116	Emotional Awareness, Relationship Quality, and Satisfaction in Patients With Parkinson's Disease and Their Spousal Caregivers. <i>Journal of Nervous and Mental Disease</i> , 2015 , 203, 646-9	1.8	13
115	Alpha-synuclein repeat variants and survival in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1053-	-₹	11
114	Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study. <i>Psychiatry Research</i> , 2014 , 215, 448-52	9.9	71
113	FACIAL EMOTION EXPRESSIVENESS AND FACIAL EMOTION RECOGNITION IN PARKINSON'S DISEASE: HOW MUCH DOES ALEXITHYMIA COUNT?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, e3-e3	5.5	1
112	Phenotypic variability of PINK1 expression: 12 Years' clinical follow-up of two Italian families. <i>Movement Disorders</i> , 2014 , 29, 1561-6	7	33
111	Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 665-7	3.6	
110	Freezing of gait in Parkinson's disease: the paradoxical interplay between gait and cognition. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 824-9	3.6	20

109	Reliability of clinical diagnosis of dystonia. <i>Neuroepidemiology</i> , 2014 , 43, 213-9	5.4	11
108	Punding behavior in bipolar disorder type 1: case report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014 , 26, E8-9	2.7	4
107	Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus?. <i>Movement Disorders</i> , 2014 , 29, 921-7	7	35
106	Long-term effects of pedunculopontine nucleus stimulation for Pisa syndrome. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1445-6	3.6	19
105	Dopaminergic agents and nutritional status in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1543	-7 ₇	20
104	Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. <i>Clinical Neuropharmacology</i> , 2014 , 37, 91-5	1.4	13
103	Cardiovascular autonomic nervous system evaluation in Parkinson disease and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2014 , 336, 197-202	3.2	25
102	Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders 2014 , 51-93		1
101	Transcranial magnetic stimulation predicts functional recovery after botulinum toxin treatment in stroke patients. <i>International Journal of Stroke</i> , 2013 , 8, E40	6.3	
100	Neuropsychological features of patients with Parkinson's disease and impulse control disorders. <i>Neurological Sciences</i> , 2013 , 34, 1207-13	3.5	48
99	The role of small intestinal bacterial overgrowth in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1241-9	7	194
98	The influence of gender on phenotype and disease progression in patients with Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 192-7	3.6	76
97	Tremor in primary adult-onset dystonia: prevalence and associated clinical features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 404-8	5.5	51
96	Epidemiological, clinical, and molecular study of a cohort of Italian Parkinson disease patients: association with glutathione-S-transferase and DNA repair gene polymorphisms. <i>Cellular and Molecular Neurobiology</i> , 2013 , 33, 673-80	4.6	14
95	Aristotle's illusion reveals interdigit functional somatosensory alterations in focal hand dystonia. <i>Brain</i> , 2013 , 136, 782-9	11.2	14
94	Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. <i>Movement Disorders</i> , 2013 , 28, 1142-5	7	24
93	Lithium treatment in patients with Huntington disease and suicidal behavior. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 819-21	1.7	19
92	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9	3.2	38

91	Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 559-61	7	69
90	Psychogenic facial movement disorders: clinical features and associated conditions. <i>Movement Disorders</i> , 2012 , 27, 1544-51	7	73
89	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012 , 259, 2621-31	5.5	154
88	Nigro-striatal involvement in primary progressive freezing gait: insights into a heterogeneous pathogenesis. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 578-84	3.6	17
87	Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. <i>Movement Disorders</i> , 2012 , 27, 1447-50	7	31
86	Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1937-48	8.8	39
85	Status dystonicus: predictors of outcome and progression patterns of underlying disease. <i>Movement Disorders</i> , 2012 , 27, 783-8	7	64
84	Retrospective evaluation of the dose equivalence of Botox([]) and Dysport ([]) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. <i>Neurological Sciences</i> , 2012 , 33, 261-7	3.5	21
83	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012 , 33, 585-93	3.5	15
82	Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's Disease and other disorders. <i>Current Drug Safety</i> , 2012 , 7, 63-75	1.4	38
81	Unilateral extradural motor cortex stimulation is safe and improves Parkinson disease at 1 year. <i>Neurosurgery</i> , 2012 , 71, 815-25	3.2	26
80	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. <i>Neurobiology of Aging</i> , 2011 , 32, 548.e9-18	5.6	46
79	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011 , 32, 2108.e1-5	5.6	15
78	Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 2386-7	5.6	11
77	Translation initiator EIF4G1 mutations in familial Parkinson disease. <i>American Journal of Human Genetics</i> , 2011 , 89, 398-406	11	213
76	Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 313-9	7	81
75	Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism. <i>Movement Disorders</i> , 2011 , 26, 553-6	7	53
74	Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 889-92	7	115

(2008-2010)

73	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. <i>Brain</i> , 2010 , 133, 2664-76	11.2	295
72	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010 , 257, 5-14	5.5	115
71	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 578-86	7	319
70	Punding in Parkinson's disease: the impact of patient's awareness on diagnosis. <i>Movement Disorders</i> , 2010 , 25, 1297-9	7	12
69	Rare and serious cardiac side effects during ropinirole titration. <i>Movement Disorders</i> , 2010 , 25, 1509-10	7	7
68	Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering 2009 , 112-130		1
67	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. <i>Movement Disorders</i> , 2009 , 24, 557-63	7	60
66	Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1154-61	7	114
65	GIGYF2 variants are not associated with Parkinson's disease in Italy. <i>Movement Disorders</i> , 2009 , 24, 1867-8; author reply 1868-9	7	17
64	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1641-9	7	919
63	Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. <i>Movement Disorders</i> , 2009 , 24, 2350	- <i>7</i> 7	32
62	Mutation screening of the DYT6/THAP1 gene in Italy. <i>Movement Disorders</i> , 2009 , 24, 2424-7	7	36
61	Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. <i>Neurotoxicity Research</i> , 2009 , 15, 224-31	4.3	50
60	Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. <i>European Journal of Neurology</i> , 2009 , 16, 392-8	6	33
59	Tetrabenazine. Expert Opinion on Pharmacotherapy, 2009 , 10, 2883-96	4	43
58	Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment. <i>Journal of Voice</i> , 2008 , 22, 365-72	1.9	86
57	Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. <i>Drug and Alcohol Dependence</i> , 2008 , 96, 178-82	4.9	52
56	The long-term effect of tetrabenazine in the management of Huntington disease. <i>Clinical Neuropharmacology</i> , 2008 , 31, 313-8	1.4	44

55	Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. <i>Journal of Neurology</i> , 2008 , 255, 1372-7	5.5	28
54	Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. <i>Movement Disorders</i> , 2008 , 23, 751-5	7	42
53	High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 1916-9	7	29
52	GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. <i>Movement Disorders</i> , 2008 , 23, 1289-92	7	62
51	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008 , 29, 565	4.7	58
50	Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients. <i>Movement Disorders</i> , 2007 , 22, 324-7	7	35
49	Dystonia gravidarum: a new case with a long follow-up. <i>Movement Disorders</i> , 2007 , 22, 564-6	7	9
48	Management of status dystonicus: our experience and review of the literature. <i>Movement Disorders</i> , 2007 , 22, 963-8	7	81
47	Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis. <i>Journal of Neurology</i> , 2007 , 254, 113-4	5.5	14
46	Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 299-303	3.6	46
45	Management of bladder, prostatic and pelvic floor disorders. <i>Neurotoxicity Research</i> , 2006 , 9, 161-72	4.3	8
44	Punding and computer addiction in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1217-8	7	31
43	Analysis of blink rate in patients with blepharospasm. <i>Movement Disorders</i> , 2006 , 21, 1225-9	7	37
42	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1232-5	7	18
41	Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. <i>Movement Disorders</i> , 2006 , 21, 1411-8	7	32
40	Onset and progression of primary torsion dystonia in sporadic and familial cases. <i>European Journal of Neurology</i> , 2006 , 13, 1083-8	6	14
39	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005 , 13, 748-52	5.3	169
38	Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 695-701	6.1	53

(2001-2004)

37	PINK1 mutations are associated with sporadic early-onset parkinsonism. <i>Annals of Neurology</i> , 2004 , 56, 336-41	9.4	397
36	Phenotypic characterization of DYT13 primary torsion dystonia. <i>Movement Disorders</i> , 2004 , 19, 200-6	7	30
35	Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. <i>Movement Disorders</i> , 2004 , 19 Suppl 8, S146-56	7	21
34	Hereditary early-onset Parkinson's disease caused by mutations in PINK1. <i>Science</i> , 2004 , 304, 1158-60	33.3	2586
33	Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. <i>Advances in Neurology</i> , 2004 , 94, 171-8		4
32	Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1439-40	0.7	54
31	Abnormal gating of somatosensory inputs in essential tremor. Clinical Neurophysiology, 2003, 114, 120-	94.3	25
30	Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. <i>Urology</i> , 2003 , 62, 259-64; discussion 264-5	1.6	181
29	Park6-linked parkinsonism occurs in several european families. <i>Annals of Neurology</i> , 2002 , 51, 14-18	9.4	81
28	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. <i>Annals of Neurology</i> , 2002 , 52, 849-53	9.4	179
27	Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia?. <i>Movement Disorders</i> , 2002 , 17, 1058-63	7	29
26	Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. <i>Movement Disorders</i> , 2002 , 17, 1371-4	7	228
25	Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. <i>Surgery</i> , 2002 , 131, 179-84	3.6	129
24	Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. <i>Neurological Sciences</i> , 2001 , 22, 95-6	3.5	15
23	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13B6.32 in an Italian family with cranial-cervical or upper limb onset. <i>Annals of Neurology</i> , 2001 , 49, 362-366	9.4	90
22	Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. <i>American Journal of Medicine</i> , 2001 , 111, 163-4	2.4	37
21	Anterior rectocele due to obstructed defecation relieved by botulinum toxin. <i>Surgery</i> , 2001 , 129, 524-9	3.6	27
20	Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. <i>American Journal of Human Genetics</i> , 2001 , 68, 895-900	11	389

19	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13B6.32 in an Italian family with cranial-cervical or upper limb onset 2001 , 49, 362		3
18	Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. <i>Diseases of the Colon and Rectum</i> , 2000 , 43, 376-80	3.1	59
17	Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. <i>American Journal of Surgery</i> , 2000 , 179, 46-50	2.7	109
16	Zolpidem in progressive supranuclear palsy. New England Journal of Medicine, 1999, 341, 543-4	59.2	85
15	A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. <i>New England Journal of Medicine</i> , 1999 , 341, 65-9	59.2	317
14	Italian family with cranial cervical dystonia: clinical and genetic study. <i>Movement Disorders</i> , 1999 , 14, 820-5	7	22
13	Botulinum toxin in motor disorders. <i>Current Opinion in Neurology</i> , 1999 , 12, 447-56	7.1	9
12	Relief by botulinum toxin of voiding dysfunction due to prostatitis. <i>Lancet, The</i> , 1998 , 352, 625	40	39
11	A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. <i>New England Journal of Medicine</i> , 1998 , 338, 217-20	59.2	305
10	Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: long-term results after two different dosage regimens. <i>Annals of Surgery</i> , 1998 , 228, 664-9	7.8	111
9	Severe constipation in Parkinson's disease relieved by botulinum toxin. <i>Movement Disorders</i> , 1997 , 12, 764-6	7	67
8	Analysis of blink rate patterns in normal subjects. <i>Movement Disorders</i> , 1997 , 12, 1028-34	7	315
7	Review article: the use of botulinum toxin in the alimentary tract. <i>Alimentary Pharmacology and Therapeutics</i> , 1995 , 9, 599-604	6.1	36
6	Genetically determined cholinergic deficiency in the forebrain of C57BL/6 mice. <i>Brain Research</i> , 1994 , 637, 181-9	3.7	18
5	Botulinum toxin for chronic anal fissure. <i>Lancet, The</i> , 1994 , 344, 1127-8	40	156
4	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group. <i>Italian Journal of Neurological Sciences</i> , 1992 , 13, 735-9		9
3	Transient alternating hemichorea as presenting sign of progressive supranuclear palsy. <i>Italian Journal of Neurological Sciences</i> , 1991 , 12, 99-101		1
2	Aging is associated with a diffuse impairment of forebrain cholinergic neurons. <i>Brain Research</i> , 1990 , 508, 51-9	3.7	108

LIST OF PUBLICATIONS

Age-dependent loss of cholinergic neurones in basal ganglia of rats. *Brain Research*, **1988**, 455, 177-81 3.7 46